Tim Watts, CFO at Shield Therapeutics #STX presenting at our Life Sciences Investor Briefing Watch Now

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price: 1,671.60
Bid: 1,659.20
Ask: 1,660.20
Change: 13.80 (0.83%)
Spread: 1.00 (0.06%)
Open: 1,649.20
High: 1,678.20
Low: 1,646.40
Yest. Close: 1,657.80
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

TOP NEWS: GlaxoSmithKline Profit Up In First Half; Guidance Improved

Wed, 24th Jul 2019 12:35

(Alliance News) - GlaxoSmithKline PLC on Wednesday said its profit rose almost 50% in the first half of the year due to strong performances from its Vaccines and Consumer Healthcare divisions.

Glaxo also upgraded it guidance and now expects 2019 adjusted earnings per share to decline by between 3% and 5% at constant currency, having previously forecast 5% to 9% decline.

The pharma giant posted pretax profit of GBP2.56 billion for the six months to June 30, up 49% from GBP1.72 billion the year before. Adjusted earnings per share for the period stood at 60.6 pence versus 52.7p a year ago.

Revenue was GBP15.47 billion, a 6.5% increase from GBP14.53 billion in the first half of 2018, with Respiratory sales boosted by drugs Trelegy Ellipta and Nucala.

Moreover, shingles vaccine Shingrix and the company's meningitis vaccines boosted overall Vaccines revenue, with a 23% increase in second quarter Vaccines revenue at constant currency.

In the second quarter as a whole, Glaxo reported a profit of GBP1.26 billion on revenue of GBP7.81 billion. This was more than twice its profit of GBP614 million in the same quarter of 2018 and a 6.8% increase in revenue from GBP7.31. Adjusted earnings per share amounted to 30.5p versus 28.1p.

The company maintained its quarterly dividend at 19p per share, in line with its goal of maintaining 80p per share dividend for the year.

Looking ahead, should exchange rates be maintained at current levels, the company expects a positive 2% boost to revenue growth. If exchange rates were at the same level at 2018, the positive impact to adjusted earnings per share growth would be approximately 4%.

Glaxo Chief Executive Emma Walmsley said: "GSK delivered continued good operating performance in Q2 despite the loss of exclusivity of Advair. We are increasing our expectations for the year and have updated our guidance for 2019."

"We remain focused on strengthening our R&D pipeline and the execution of new product launches. Positive clinical data received so far this year offer significant new opportunities for products in Oncology, HIV and Respiratory and we expect more important readouts in the second half of the year. We also expect to complete our joint venture with Pfizer shortly, laying the foundation for the creation of two great companies: one in Pharmaceuticals/Vaccines; one in Consumer Healthcare."

Earlier on Wednesday, Glaxo announced it has appointed former AstraZeneca PLC finance chief Jonathan Symonds to replace outgoing Chair Philip Hampton at the start of September.

Symonds will replace Hampton - who has held the post since 2015 - after he announced his intention to lave in January.

Shares in Glaxo were up 0.3% on Wednesday at 1,665.00p.

More News

BROKER RATINGS SUMMARY: Morgan Stanley Raises SSE To Overweight

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:----------FTSE 100----------DEUTSCHE BANK RAISES RENTOKIL INITIAL

10 Sep 19 09:32

Aurora Investment Trust Net Assets Rise But Total Interim Return Lags

(Alliance News) - Aurora Investment Trust PLC on Monday said its net asset value rose in the first six months of the year but total return lagged behind its benchmark index.At June 30, a of

9 Sep 19 12:12

BROKER RATINGS SUMMARY: Deutsche Bank Raises BHP And Cuts Antofagasta

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:----------FTSE 100----------DEUTSCHE BANK RAISES BHP

4 Sep 19 09:32

Tuesday broker round-up

(Sharecast News) - easyJet: Kepler Cheuvreux downgrades to reduce with a target price of 820p.

3 Sep 19 12:59

BROKER RATINGS SUMMARY: Deutsche Bank Starts Taylor Wimpey At Buy

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:----------FTSE 100----------DEUTSCHE BANK INITIATES TAYLOR WIMPEY

3 Sep 19 09:40

LONDON MARKET OPEN: Ferguson-Wolseley Rises; Pound Falls Below USD1.20

(Alliance News) - Stock prices in London opened mixed on Tuesday, with Ferguson the best blue-chip performer after the company decided to split its UK and US operations, while the pound fell below

3 Sep 19 08:49

Monday broker round-up

(Sharecast News) - Beazley: UBS upgrades to buy with a target price of 650p.

2 Sep 19 13:16

Former Glaxo Vice President To Lead C4X Discovery Advisory Network

(Alliance News) - C4X Discovery Holdings PLC on Monday said it is forming a drug discovery advisory network chaired by "renowned industry veteran" Robin Carr.Shares in C4X were up

2 Sep 19 12:02

BROKER RATINGS SUMMARY: Goldman Sachs Says Buy Unilever, Sell M&S

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday afternoon:----------FTSE 100----------GOLDMAN SACHS WITH

2 Sep 19 09:41

BROKER RATINGS SUMMARY: UBS Raises Greggs; Peel Hunt Lifts Chesnara

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday afternoon and Wednesday morning:----------FTSE 100----------KEPLER RAISES

28 Aug 19 09:37

GlaxoSmithKline's Dreamm-2 Multiple Myeloma Trial Results Encouraging

(Alliance News) - GlaxoSmithKline PLC on Friday reported positive headline results from its Dreamm-2 study of belantamab mafodotin in multiple myeloma.The study, which involved 196 patients

23 Aug 19 07:46

GlaxoSmithKline reveals positive results from belantamab mafodotin trial

(Sharecast News) - GlaxoSmithKline announced positive headline results from the pivotal 'DREAMM-2' open-label, randomised study of two doses of belantamab mafodotin on Friday.

23 Aug 19 07:29

Glaxo's ViiV Reports Positive Study Results Of HIV-Treatment Regimen

(Alliance News) - GlaxoSmithKline PLC on Thursday said ViiV Healthcare reported positive headline results from its global phase III ATLAS-2M study.ViiV Healthcare is a specialist HIV owned

22 Aug 19 08:20

GlaxoSmithKline upbeat on latest test results from ViiV Healthcare

(Sharecast News) - GlaxoSmithKline reported on Thursday that its specialist HIV company ViiV Healthcare had announced positive headline results from its phase 3 'ATLAS-2M' study of the investigational, long-acting, injectable, two-drug regimen (2DR) of its cabotegravir and Janssen's rilpivirine for the treatment of HIV.

22 Aug 19 07:29

Glaxo Submits Japanese Application For Daprodustat Anaemia Drug

(Alliance News) - GlaxoSmithKline PLC on Wednesday said it has submitted a new drug application in Japan for anaemia drug daprodustat.The application was submitted to the Japanese Ministry

21 Aug 19 08:38

Login to your account

Don't have an account? Click here to register.